Author Archives: admin001

BriaCell Announces First Patient Dosed with Bria-OTS(TM) in Metastatic Breast Cancer Study

Phase 1/2 dose escalation study to evaluate BriaCell’s personalized next generation immunotherapy treatment in metastatic ...

BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference

BriaCell’s clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer (Bria-PROS+™) generate robust ...

BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13

Five BriaCell poster presentations to highlight updated survival and key biomarker data from Phase 2 ...

BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study

35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT™ combination with immune ...

BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients

FDA has authorized the Expanded Access Policy (EAP) to help metastatic breast cancer patients in ...

ASCO 2018: Interview with Dr. Saveri Bhattacharya on the ongoing Ph I/IIa clinical trial with BriaCell’s lead candidate, Bria-IMT™, in advanced breast cancer

ASCO 2018: Interview with Dr. Saveri Bhattacharya on the ongoing Ph I/IIa clinical trial with ...

BriaCell Announces Closing of Warrant Incentive Program

Berkeley, CA and Vancouver, BC – December 21, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or ...

Bill Williams M.D. from BriaCell on CEO Money

Click here to read more ...

Expanding Breast Cancer Treatment Options: A Q&A with BriaCell on their Cancer Immunotherapy and their Pipeline

Expanding Breast Cancer Treatment Options: A Q&A with BriaCell on their Cancer Vaccine and their ...

BriaCell Announces Warrant Incentive Program

Berkeley, CA and Vancouver, BC – October 13, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or ...